Newsletter | Edition N.4 | 2014
View this email in your browser

Glythera relocated to Newcastle-upon-Tyne in 2012, following investment from IP Group and the Finance for Business North East Technology Fund which underpinned the commercialisation of its core, enabling technology platforms. 

Glythera is an emerging biotechnology company focused on developing antibody-based therapies for the treatment of cancer as well as broader based therapeutics. 

Our main goal is to develop effective therapies to improve patients’ lives. Our mission is to enable improved clinical regimes through creation of the next generation of safe, efficacious biotherapeutic products in the oncology and therapeutics markets. With substantial experience and expertise in bioprocessing and chemistry development, we have a proven track record of supporting programs centred on our core technologies - PermaLink™ and PermaCarb™.

We are open to opportunities for technology out-licensing, collaboration or provision of full service business models for the use of PermaLink™ or PermaCarb™.

If you are looking to improve control, efficiency and post-transitional modification in the development of protein conjugates and biotherapeutics then our dedicated team would be happy to discuss opportunities with you. 

Herschel Annex, King's Road, Newcastle-upon-Tyne
NE1 7RU, UK.
  +44 (0) 191 2223836
Google +
Google +
Welcome to Glythera’s monthly newsletter and thank you for your continued interest in us. The team is working hard on development of our PermaLink™ and PermaCarb™ technologies, details of which are available on request.
Last month we traveled across Europe to attend a number of interesting meetings including the Antibody Drug Conjugates Congress in Barcelona where discussions ranged from developments in innovative payloads to approaches for optimizing ADC processing and CMC. 
As part of our continued commitment to promoting science in the North East of England we recently helped out at a CV workshop at Newcastle University and supported a careers day at York University where we met some extremely enthusiastic students keen to contribute their talents to the Biotech industry.
Do visit our website to find out where you can meet us next and please get in touch if you have any questions.
Best Regards,
Jenny Thirlway
Technical Director, Glythera

Glythera - News
Glythera is delighted to announce the launch of our Library page on Glythera’s Website. We're proud to reveal our Posters, our Newsletters and our brand new Non-confidential slides. We invite everyone to visit our website at

Glythera is now on Google+! Add us to your circles!
Follow us and we'll keep you up to date with all our news and we'll let you know where you can meet us at upcoming industry events.
It's a chance for you to let us know what you think too. 
We are looking forward to exchanging with you!
Glythera - Knowledge Transfer

Glythera - Upcoming Events
Glythera’s CEO David Simpson will attend UK CEO and Investor Forum 2014 place on Thursday 10 and Friday 11 July at Lingfield Park, Surrey
Glythera’s CEO David Simpson will attend BIO-Europe held in Frankfurt - Germany, 3 – 5 November 2014
Glythera’s CEO David Simpson will attend FT Global Pharmaceutical and Biotechnology conference 2014 taking place on 17-18 November at the Marriott Grosvenor, London
Visit Newcastle upon Tyne
Over 38 million people have experienced BODY WORLDS in over 90 cities worldwide including Tokyo, New York, Los Angeles and Mexico City - now here’s your chance to see it in Newcastle at Life Science Centre
Copyright © *2014* *Glythera*, All rights reserved.
Please consider the environment before printing this Newsletter

Our mailing address is:
Glythera · Herschel Annex, King's Road · Newcastle Upon Tyne, Tyne and Wear NE1 7RU · United Kingdom

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp